Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: A comparative, observer-blind, randomised, controlled trial

The Lancet Infectious Diseases

Volumn 16, Issue 3, 2016, Pages 321-330

  Sáez Llorens, Xavier ^a   Clemens, Ralf ^b   Leroux Roels, Geert ^c   Jimeno, José ^d   Clemens, Sue Ann Costa ^e   Weldon, William C ^f   Oberste, M Steven ^f   Molina, Natanael ^d   Bandyopadhyay, Ananda S ^g  

^a Hospital del Niño   (Panama)

^b Global Research in Infectious Diseases   (Brazil)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d Vaxtrials   (Panama)

^e Instituto de Pós Graduação Médica Carlos Chagas   (Brazil)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HEPATITIS B VACCINE; INACTIVATED POLIOMYELITIS VACCINE; INACTIVATED VACCINE; MONOVALENT HIGH DOSE INACTIVATED HUMAN POLIOVIRUS 2 VACCINE; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG; POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; HUMAN POLIOVIRUS 2; IMMUNIZATION; IMMUNOGENICITY; INFANT; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SINGLE DRUG DOSE; VIRUS SHEDDING; BLOOD; FECES; IMMUNOLOGY; POLIOMYELITIS; POLIOMYELITIS VIRUS; PROCEDURES; SINGLE BLIND PROCEDURE; VACCINATION; VIROLOGY;

ANTIBODIES, VIRAL; FECES; FEMALE; HUMANS; INFANT; MALE; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; SINGLE-BLIND METHOD; VACCINATION; VIRUS SHEDDING;

EID: 84959130392     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00488-0     Document Type: Article

References (27)

1. Bandyopadhyay AS, Garon J, Seib K, et al. Polio vaccination: past, present and future. Future Microbiol 2015, 10:791-808.
2. Global Polio Eradication Initiative. Polio this week 2015, WHO, World Health Organization, Geneva, Switzerland, (accessed Nov 23, 2015). http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx.
3. Platt LR, Estívariz CF, Sutter RW Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis 2014, 210(suppl 1):S380-S389.
4. Polio eradication & endgame; midterm review July 2015 Polio Global Eradication Initiative, (accessed Nov 23, 2015). http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/GPEI-MTR_July2015.pdf.
5. Polio Eradication & Endgame Strategic Plan 2013-2018 Global Polio Eradication Initiative, (accessed Nov 23, 2015). http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP_EN_US.pdf.
6. Polio vaccines: WHO position paper, January 2014. Wkly Epidemiol Rec 2014, 89:73-92. WHO.
7. SAGE confirms global polio vaccine switch date as April 2016 Global Polio Eradication Initiative, (accessed Nov 23, 2015). http://www.polioeradication.org/mediaroom/newsstories/SAGE-confirms-global-polio-vaccine-switch-date-as-April-2016/tabid/526/news/1307/Default.aspx?popUp=true.
8. Salk J, Cohen H, Fillastre C, et al. Killed poliovirus antigen titration in humans. Dev Biol Stand 1977, 41:119-132.
9. Salk J, Van Wezel AL, Stoeckel P, et al. Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis. Dev Biol Stand 1980, 47:181-198.
10. Salk J, Stoeckel P, van Wezel AL, et al. Antigen content of inactivated poliovirus vaccine for use in a one- or two-dose regimen. Ann Clin Res 1982, 14:204-212.
11. Vidor E, Mescheivitz C, Plotkin S Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Ped Infect Dis J 1997, 16:312-322.
12. Swartz TA, Handsher R, Stoeckel P, et al. Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule. Eur J Epidemiol 1989, 5:143-145.
13. WHO Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser 1982, 673:1-180. WHO.
14. Ferguson M, Wood DJ, Minor PD Antigenic structure of poliovirus in inactivated vaccines. J Gen Virol 1993, 74:685-690.
15. Simasathien S, Migasena S, Beuvery C, et al. Comparison of enhanced potency inactivated poliovirus vaccine (eIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants. Scand J Infect Dis 1994, 26:731-738.
16. Mohammed AJ, AlAwaidy S, Bawikar S, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010, 362:2351-2359.
17. Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013, 368:416-424.
18. O'Ryan M, Bandyopadhyay AS, Villena R, et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis 2015, 15:1273-1282.
19. Sutter RW, John TJ, Jain H, et al. Immunogenicity of a bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 2010, 376:1682-1688.
20. Karber G Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Pathol Pharmakol 1931, 162:480-483.
21. Polio laboratory manual, 4th edition. WHO/IVB/04.10 2004, WHO, World Health Organization, Geneva, (accessed Nov 23, 2015). http://apps.who.int/iris/bitstream/10665/68762/1/WHO_IVB_04.10.pdf.
22. Sutter RW, Bahl S, Deshpande JM, et al. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. Lancet 2015, published online Sep 17. http://dx.doi.org/10.1016/S0140-6736(15)00237-8.
23. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med 2007, 356:1536-1544. The Cuba IPV Study Collaborative Group.
24. Hird TR, Grassly NC Systematic review of mucosal immunity inducted by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus shedding. PLoS Pathog 2012, 8:e1002599.
25. John J, Giri S, Karthikeyan AS, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet 2014, 384:1505-1512.
26. Jafari H, Deshpande JM, Sutter RW, et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science 2014, 345:922-925.
27. Availability and price of inactivated polio vaccine Global Polio Eradication Initiative (GPEI), (accessed Nov 23, 2015). http://www.polioeradication.org/tabid/488/iid/354/Default.aspx.